- Targeted Drugs
- Purine Analogues
- Alkylating Agents
- Other Drugs
Chronic Lymphocytic Leukemia Treatment Market size was valued at 10.85 billion in 2022 and is poised to grow at a significant CAGR of 10.55% from 2023-29. Chronic lymphocytic leukemia or ?-cell chronic lymphocytic leukemia, which is the common type of leukemia of the WBC in adults. ?-cell lymphocytes are a type of white blood cells, which produce in the bone marrow, develop in lymph nodes. These cells produce antibodies which fight against infection. In chronic lymphocytic leukemia, ?-cells produce in an uncontrolled manner and accumulate in blood and bone marrow, and they crowd out healthy blood cells. Majorly, chronic lymphocytic leukemia occurs in adults, however, sometimes it occurs in the teenagers and children. Chronic lymphocytic leukemia is diagnosed by using complete blood count test, flow cytometry test, gene tests, and bone marrow tests. The global market for chronic lymphocytic leukemia treatment is expected to grow at a significant CAGR due to increase in the prevalence of chronic lymphocytic leukemia. According to WHO chronic lymphocytic leukemia is more prominent in the developed world such as North America and Europe due to genetic factors. The global incidence of chronic lymphocytic leukemia was 94,960 in 2008 with the developing countries, which is increased to 123,379 in 2010 and predicted to reach 282,683 new cases for 2020. The global chronic lymphocytic leukaemia treatment market is in developing stage in nature with several international players operating in the chronic lymphocytic leukemia treatment. Conventionally, chemo drugs are dominating the chronic lymphocytic leukemia treatment market. For instance, Rituximab, Imbruvica, and Idelalisib are the chemo drugs used in the treatment of chronic lymphocytic leukemia patients in combination or alone. Efficacy of these drugs in chronic lymphocytic leukemia is potentially replaced chemoimmunotherapy. Co-development and collaboration agreements are some of the key strategies adopted by some market players. For instance, GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of chronic lymphocytic leukemia. Similarly, venetoclax by Roche, in collaboration with AbbVie, received approval from the US FDA for the treatment of chronic lymphocytic leukemia. With an increasing number of drug approvals, the chronic lymphocytic leukemia treatment market is anticipated to post a positive outlook over the forecast period.
Fastest Growing Market
Increase in aging population, excessive exposure to carcinogenic chemicals, and genetical blood disorders are the major drivers for the growth of global market. Furthermore, growing disease awareness, and rising incidences of comorbidities may accelerates the growth of the market. Increased research and development in oncology sector, introduction of novel therapies, promising pipeline products, and new innovation in drug development helps in the growth of chronic lymphocytic leukemia treatment market. However, the high cost of the treatment for chronic lymphocytic leukemia and stringent regulatory policies might hamper the growth of global market over the forecast period.
The chronic lymphocytic leukemia treatment Market is projected to expand at a CAGR of 10.55% during the forecast period
Genzyme Corporation, Ono pharmaceuticals Co. Ltd, F. Hoffmann-La Roche Ltd, AbbVie Inc, Arno Therapeutics Inc, Infinity Pharmaceuticals
Asia-Pacific is the fastest-growing region for chronic lymphocytic leukemia treatment Market
Chronic Lymphocytic Leukemia Treatment Market size was valued at 10.85 billion in 2022, is expected to reach USD 19.44 billion by 2029 and is poised to grow at a significant CAGR of 10.55% from 2023-29.